HUNTSVILLE, Ala., Sept. 5 /PRNewswire/ -- Expression Genetics, Inc. (EGEN) announced today that the company's novel TheraPlas(R) cancer drug has been selected as one of the Top 10 most promising oncology products in development available for strategic partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committee considered the most attractive oncology opportunities the industry has to offer," said Roger Longman, Managing Director of Windhover Information. "Winners have met rigorous criteria including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications, and corporate stability."
"We are honored that Windhover has recognized the potential of EGEN-001 to address serious unmet needs in cancer treatment," said Dr. Danny H. Lewis, president and chief executive officer of Expression Genetics. "With its unique profile, proprietary delivery system technology, and results to date, EGEN-001 has demonstrated ability to address a number of tumor types and represents a potentially important new approach to treat a wide range of cancers. We look forward to continuing our efforts to advance this promising product compound through clinical development."
The selection committee was led by Marc Wortman, Ph.D., contributing
writer to Windhover's In Vivo and Start Up, and a team from Campbell
Alliance, a leading business development strategy consulting firm. Drawing
on the analytic resources of these organizations, the group evaluated
hundreds of compounds currently in development for the treatmen
|SOURCE Expression Genetics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved